Naltrexone in the short-term decreases antiparkinsonian response to L-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys

Neuropharmacology

Volumn 49, Issue 2, 2005, Pages 165-173

  Samadi, Pershia ^a,b   Grégoire, Laurent ^a   Tahar, Abdallah Hadj ^a   Di Paolo, Thérèse ^a,b   Rouillard, Claude ^a,b   Bédard, Paul J ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Dyskinesia; MPTP; Naltrexone; Opioid; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; LEVODOPA; NALTREXONE; OPIATE ANTAGONIST;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; FEMALE; MONKEY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DYSKINESIAS; FEMALE; LEVODOPA; MACACA FASCICULARIS; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; OVARIECTOMY; PARKINSONIAN DISORDERS; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 21644478361     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2005.02.009     Document Type: Article

References (49)

1. D. Berg, G. Becker, and K. Reiners Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica J. Neural Transm. 106 1999 725 728
2. E. Bezard, C.E. Gross, and J.M. Brotchie Presymptomatic compensation in Parkinson's disease is not dopamine-mediated Trends Neurosci. 26 2003 215 221
3. P.J. Blanchet, P. Allard, L. Grégoire, F. Tardif, and P.J. Bédard Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients Can. J. Neurol. Sci. 23 1996 189 193
4. F. Blandini, G. Nappi, C. Tassorelli, and E. Martignoni Functional changes of the basal ganglia circuitry in Parkinson's disease Prog. Neurobiol. 62 2000 63 88
5. D.J. Brooks, P. Piccini, N. Turjanski, and M. Samuel Neuroimaging of dyskinesia Ann. Neurol. 47 2000 S154 S158
6. J.M. Brotchie, B. Henry, C.J. Hille, and A.R. Crossman Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease Adv. Neurol. 78 1998 41 52
7. F. Calon, S. Birdi, A.H. Rajput, O. Hornykiewicz, P.J. Bédard, and T. Di Paolo Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias J. Neuropathol. Exp. Neurol. 61 2002 186 196
8. F. Calon, T.A. Hadj, P.J. Blanchet, M. Morissette, R. Grondin, M. Goulet, J.P. Doucet, G.S. Robertson, E. Nestler, T. Di Paolo, and P.J. Bédard Dopamine-receptor stimulation: biobehavioral and biochemical consequences Trends Neurosci. 23 2000 S92 S100
9. K. Campbell, and A. Bjorklund Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum Eur. J. Neurosci. 6 1994 1371 1383
10. B.L. Crabtree Review of naltrexone, a long-acting opiate antagonist Clin. Pharmacol. 3 1984 273 280
11. M.A. Cenci, C.S. Lee, and A. Bjorklund l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10 1998 2694 2706
12. J.M. Delfs, H. Kong, A. Mestek, Y. Chen, L. Yu, T. Reisine, and M.F. Chesselet Expression of mu opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level J. Comp. Neurol. 345 1994 46 68
13. S. Fox, M. Silverdale, M. Kellett, R. Davies, M. Steiger, N. Fletcher, A. Crossman, and J. Brotchie Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease Mov. Disord. 19 2004 554 560
14. J.T. Greenamyre Glutamatergic influences on the basal ganglia Clin. Neuropharmacol. 24 2001 65 70
15. J. Guridi, and J.A. Obeso The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma Brain 124 2001 5 19
16. A. Hadj Tahar, A. Ekesbo, L. Grégoire, E. Bangassoro, K.A. Svensson, J. Tedroff, and P.J. Bédard Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on l-DOPA-induced dyskinesias in MPTP monkeys Eur. J. Pharmacol. 412 2001 247 254
17. A. Hadj Tahar, L. Grégoire, A. Darre, N. Belanger, L. Meltzer, and P.J. Bédard Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys Neurobiol. Dis. 15 2004 171 176
18. O.K. Hassani, M. Mouroux, and J. Feger Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus Neuroscience 72 1996 105 115
19. B. Henry, S. Duty, S.H. Fox, A.R. Crossman, and J.M. Brotchie Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease Exp. Neurol. 183 2003 458 468
20. B. Henry, S.H. Fox, A.R. Crossman, and J.M. Brotchie Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Exp. Neurol. 171 2001 139 146
21. M.T. Herrero, R. Levy, M. Ruberg, M.R. Luquin, J. Villares, J. Guillen, B. Faucheux, F. Javoy-Agid, J. Guridi, Y. Agid, J.A. Obeso, and E.C. Hirsch Consequence of nigrostriatal denervation and l-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum Neurology 47 1996 219 224
22. C.J. Hille, S.H. Fox, Y.P. Maneuf, A.R. Crossman, and J.M. Brotchie Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease Exp. Neurol. 172 2001 189 198
23. N.R. Hughes, A.T. McKnight, G.N. Woodruff, M.P. Hill, A.R. Crossman, and J.M. Brotchie Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism Mov. Disord. 13 1998 228 233
24. Z.G. Jiang, and R.A. North Pre- and postsynaptic inhibition by opioids in rat striatum J. Neurosci. 12 1992 356 361
25. B.L. Kieffer Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides Cell. Mol. Neurobiol. 15 1995 615 635
26. H.M. Lesscher, A. Bailey, J.P. Burbach, J.M. Van Ree, I. Kitchen, and M.A. Gerrits Receptor-selective changes in mu-, delta- and kappa-opioid receptors after chronic naltrexone treatment in mice Eur. J. Neurosci. 17 2003 1006 1012
27. M. Lindskog, P. Svenningsson, B. Fredholm, P. Greengard, and G. Fisone Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons Eur. J. Neurosci. 11 1999 2182 2186
28. Y.P. Maneuf, I.J. Mitchell, A.R. Crossman, and J.M. Brotchie On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus Exp. Neurol. 125 1994 65 71
29. A.J. Manson, R. Katzenschlager, J. Hobart, and A.J. Lees High dose naltrexone for dyskinesias induced by levodopa J. Neurol. Neurosurg. Psychiatry 70 2001 554 556
30. W. Meissner, S. Dovero, B. Bioulac, C.E. Gross, and E. Bezard Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei Neurobiol. Dis. 13 2003 46 54
31. M. Morissette, R. Grondin, M. Goulet, P.J. Bédard, and T. Di Paolo Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists J. Neurochem. 72 1999 682 692
32. J.A. Obeso, C.W. Olanow, and J.G. Nutt Levodopa motor complications in Parkinson's disease Trends Neurosci. 23 2000 S2 S7
33. D. Peckys, and G.B. Landwehrmeyer Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study Neuroscience 88 1999 1093 1135
34. B. Picconi, D. Centonze, K. Hakansson, G. Bernardi, P. Greengard, G. Fisone, M.A. Cenci, and P. Calabresi Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia Nat. Neurosci. 6 2003 501 506
35. M. Quik, S. Police, J.W. Langston, and D.A. Di Monte Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not l-DOPA-induced dyskinesias in the squirrel monkey Neuroscience 113 2002 213 220
36. O. Rascol, N. Fabre, O. Blin, J. Poulik, U. Sabatini, J.M. Senard, M. Ane, J.L. Montastruc, and A. Rascol Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease Mov. Disord. 9 1994 437 440
37. P. Samadi, L. Grégoire, and P.J. Bédard Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems Neuropharmacology 45 2003 954 963
38. P. Samadi, L. Grégoire, and P.J. Bédard The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys Neurobiol. Dis. 16 2004 246 253
39. H. Schmidhammer Opioid receptor antagonists G.P. Ellis D.K. Luscombe A.W. Oxford Progress in Medical Chemistry 35 1998 Elsevier Science 83 133
40. J.S. Schneider, E. Decamp, and T. Wade Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology J. Neurosci. 19 1999 6643 6649
41. K.Z. Shen, and S.W. Johnson Presynaptic modulation of synaptic transmission by opioid receptor in rat subthalamic nucleus in vitro J. Physiol. 541 2002 219 230
42. A IPSCs in the rat globus pallidus in vitro J. Neurosci. 19 1999 4796 4803
43. H. Steiner, and C.R. Gerfen Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior Exp. Brain Res. 123 1998 60 76
44. M.F. Stromberg, T. Sengpiel, S.A. Mackler, J.R. Volpicelli, C.P. O'Brien, and W.H. Vogel Effect of naltrexone on oral consumption of concurrently available ethanol and cocaine in the rat Alcohol 28 2002 169 179
45. H. Tokuno, S. Chiken, K. Kametani, and T. Moriizumi Efferent projections from the striatal patch compartment: anterograde degeneration after selective ablation of neurons expressing mu-opioid receptor in rats Neurosci. Lett. 332 2002 5 8
46. E.M. Unterwald, and M. Cuntapay Dopamine-opioid interactions in the rat striatum: a modulatory role for dopamine D1 receptors in delta opioid receptor-mediated signal transduction Neuropharmacology 39 2000 372 381
47. M. Vila, R. Levy, M.T. Herrero, M. Ruberg, B. Faucheux, J.A. Obeso, Y. Agid, and E.C. Hirsch Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA J. Neurosci. 17 1997 765 773
48. H. Wang, K.N. Gracy, and V.M. Pickel Mu-opioid and NMDA-type glutamate receptors are often colocalized in spiny neurons within patches of the caudate-putamen nucleus J. Comp. Neurol. 412 1999 132 146
49. H. Wang, and V.M. Pickel Preferential cytoplasmic localization of delta-opioid receptors in rat striatal patches: comparison with plasmalemmal mu-opioid receptors J. Neurosci. 21 2001 3242 3250